
Esther Oomen-de Hoop

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8381055/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Confirmation of thermal dose as a predictor of local control in cervical carcinoma patients treated with state-of-the-art radiation therapy and hyperthermia. Radiotherapy and Oncology, 2019, 140, 150-158.	0.3	67
2	Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study. European Journal of Cancer, 2020, 141, 171-184.	1.3	65
3	A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients. , 2019, 7, 192.		60
4	Correlation between nivolumab exposure and treatment outcomes in non–small-cell lung cancer. European Journal of Cancer, 2019, 109, 12-20.	1.3	58
5	Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients. Thyroid, 2020, 30, 966-973.	2.4	57
6	Hyprofractionated Versus Conventionally Fractionated Radiation Therapy for Patients with Intermediate- or High-Risk, Localized, Prostate Cancer: 7-Year Outcomes From the Randomized, Multicenter, Open-Label, Phase 3 HYPRO Trial. International Journal of Radiation Oncology Biology Physics, 2020, 106, 108-115.	0.4	43
7	Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer. , 2020, 8, e000586.		39
8	Highâ€ŧhroughput isolation of circulating tumor <scp>DNA</scp> : aÂcomparison of automated platforms. Molecular Oncology, 2019, 13, 392-402.	2.1	37
9	Intratumoral Comparison of Nanoparticle Entrapped Docetaxel (CPC634) with Conventional Docetaxel in Patients with Solid Tumors. Clinical Cancer Research, 2020, 26, 3537-3545.	3.2	36
10	Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen. Cancers, 2019, 11, 403.	1.7	31
11	Survival and prognostic factors of pulmonary oligometastases treated with stereotactic body radiotherapy. Acta Oncológica, 2019, 58, 74-80.	0.8	30
12	Factors affecting local control of pulmonary oligometastases treated with stereotactic body radiotherapy. Acta Oncológica, 2018, 57, 1031-1037.	0.8	28
13	Locoregional control and survival after lymph node SBRT in oligometastatic disease. Clinical and Experimental Metastasis, 2018, 35, 625-633.	1.7	28
14	Polymorphisms in <i>SLCO1B1</i> and <i>UGT1A1</i> are associated with sorafenib-induced toxicity. Pharmacogenomics, 2016, 17, 1483-1490.	0.6	26
15	Moderate Hypofractionation in Intermediate- and High-Risk, Localized Prostate Cancer: Health-Related Quality of Life From the Randomized, Phase 3 HYPRO Trial. International Journal of Radiation Oncology Biology Physics, 2019, 103, 823-833.	0.4	22
16	Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel. Cancers, 2019, 11, 1212.	1.7	21
17	Predicting High-Grade Esophagus Toxicity After Treating Central Lung Tumors With Stereotactic Radiation Therapy Using a Normal Tissue Complication Probability Model. International Journal of Radiation Oncology Biology Physics, 2020, 106, 73-81.	0.4	21
18	Prognostic factors for local control and survival for inoperable pulmonary colorectal oligometastases treated with stereotactic body radiotherapy. Radiotherapy and Oncology, 2020, 144, 23-29.	0.3	21

#	Article	IF	CITATIONS
19	Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer. European Journal of Cancer, 2019, 121, 48-54.	1.3	20
20	The Prevalence of CD146 Expression in Breast Cancer Subtypes and Its Relation to Outcome. Cancers, 2018, 10, 134.	1.7	18
21	Relevance of Endoxifen Concentrations: Absence of Evidence Is Not Evidence of Absence. Journal of Clinical Oncology, 2019, 37, 1980-1981.	0.8	18
22	Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic Study. Clinical Pharmacology and Therapeutics, 2019, 105, 1456-1461.	2.3	17
23	Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer. Clinical Pharmacokinetics, 2022, 61, 527-537.	1.6	17
24	Influence of Enzalutamide on Cabazitaxel Pharmacokinetics: a Drug–Drug Interaction Study in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients. Clinical Cancer Research, 2018, 24, 541-546.	3.2	15
25	Influence of green tea consumption on endoxifen steady-state concentration in breast cancer patients treated with tamoxifen. Breast Cancer Research and Treatment, 2020, 184, 107-113.	1.1	14
26	Effects of Protein and Calorie Restriction on the Metabolism and Toxicity Profile of Irinotecan in Cancer Patients. Clinical Pharmacology and Therapeutics, 2021, 109, 1304-1313.	2.3	14
27	The added value of H2 antagonists in premedication regimens during paclitaxel treatment. British Journal of Cancer, 2021, 124, 1647-1652.	2.9	14
28	Influence of Cow's Milk and Esomeprazole on the Absorption of Erlotinib: A Randomized, Crossover Pharmacokinetic Study in Lung Cancer Patients. Clinical Pharmacokinetics, 2021, 60, 69-77.	1.6	12
29	Scopolaminebutyl given prophylactically for death rattle: study protocol of a randomized double-blind placebo-controlled trial in a frail patient population (the SILENCE study). BMC Palliative Care, 2018, 17, 105.	0.8	11
30	Plasma Predictive Features in Treating EGFR-Mutated Non-Small Cell Lung Cancer. Cancers, 2020, 12, 3179.	1.7	11
31	Comparison of toxicity and effectiveness between fixed-dose and body surface area-based dose capecitabine. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591983896.	1.4	10
32	Efficacy and Toxicity of Weekly Carboplatin and Paclitaxel as Induction or Palliative Treatment in Advanced Esophageal Cancer Patients. Cancers, 2019, 11, 826.	1.7	9
33	Effects of prednisone on docetaxel pharmacokinetics in men with metastatic prostate cancer: A randomized drug–drug interaction study. British Journal of Clinical Pharmacology, 2019, 85, 986-992.	1.1	9
34	Realizing better doctor-patient dialogue about choices in palliative care and early phase clinical trial participation: towards an online value clarification tool (OnVaCT). BMC Palliative Care, 2019, 18, 106.	0.8	9
35	Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib. Pharmaceutics, 2020, 12, 788.	2.0	9
36	Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy. Cancers, 2021, 13, 1370.	1.7	9

#	Article	IF	CITATIONS
37	Docetaxel Skin Exposure and Micronucleation Contributes to Skin Toxicity Caused by CPC634. Cancers, 2021, 13, 3741.	1.7	9
38	Plasma Cell-Free DNA Testing of Patients With EGFR Mutant Non–Small-Cell Lung Cancer: Droplet Digital PCR Versus Next-Generation Sequencing Compared With Tissue-Based Results. JCO Precision Oncology, 2019, 3, 1-9.	1.5	8
39	The influence of single-nucleotide polymorphisms on overall survival and toxicity in cabazitaxel-treated patients with metastatic castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology, 2020, 85, 547-553.	1.1	8
40	The Risk of QTc-Interval Prolongation in Breast Cancer Patients Treated with Tamoxifen in Combination with Serotonin Reuptake Inhibitors. Pharmaceutical Research, 2020, 37, 7.	1.7	8
41	Feasibility of Extrapolating Randomly Taken Plasma Samples to Trough Levels for Therapeutic Drug Monitoring Purposes of Small Molecule Kinase Inhibitors. Pharmaceuticals, 2021, 14, 119.	1.7	8
42	Effects of Implementation of a Standardized Palliative Care Pathway for Patients with Advanced Cancer in a Hospital: A Prospective Pre- and Postintervention Study. Journal of Pain and Symptom Management, 2021, 62, 451-459.	0.6	7
43	Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium. European Journal of Cancer, 2022, 160, 261-272.	1.3	7
44	Effect of the Proton Pump Inhibitor Esomeprazole on the Systemic Exposure of Capecitabine: Results of A Randomized Crossover Trial. Clinical Pharmacology and Therapeutics, 2022, 111, 455-460.	2.3	6
45	Influence of aprepitant and localization of the patch on fentanyl exposure in patients with cancer using transdermal fentanyl. Oncotarget, 2018, 9, 18269-18276.	0.8	5
46	Patients with primary brain tumors and COVID-19: A report from the Dutch Oncology COVID-19 Consortium. Neuro-Oncology, 2022, 24, 326-328.	0.6	5
47	Tissue Type Differences in ABCB1 Expression and Paclitaxel Tissue Pharmacokinetics in Patients With Esophageal Cancer. Frontiers in Pharmacology, 2021, 12, 759146.	1.6	5
48	Effects of smoking and body mass index on the exposure of fentanyl in patients with cancer. PLoS ONE, 2018, 13, e0198289.	1.1	3
49	Prognostic factors of local control and disease free survival in centrally located non-small cell lung cancer treated with stereotactic body radiation therapy. Acta Oncológica, 2020, 59, 809-817.	0.8	3
50	Pharmacokinetics of Sublingually Delivered Fentanyl in Head and Neck Cancer Patients Treated with Curatively Aimed Chemo or Bioradiotherapy. Cancers, 2018, 10, 445.	1.7	2
51	Self-reported quality of life and hope in phase-I trial participants: An observational prospective cohort study. European Journal of Cancer Care, 2018, 27, e12908.	0.7	2
52	Effect of Scalp Cooling on the Pharmacokinetics of Paclitaxel. Cancers, 2021, 13, 3915.	1.7	2
53	Influence of probenecid on endoxifen systemic exposure in breast cancer patients on adjuvant tamoxifen treatment. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210810.	1.4	2
54	Association between Paclitaxel Clearance and Tumor Response in Patients with Esophageal Cancer. Cancers, 2019, 11, 173.	1.7	1

#	Article	IF	CITATIONS
55	The moral and legal status of Health Care Workers in Cluster Randomized Trials: a response to Weijer and Taljaard. Journal of Clinical Epidemiology, 2019, 116, 146-149.	2.4	0
56	Influence of Genetic Variation in COMT on Cisplatin-Induced Nephrotoxicity in Cancer Patients. Genes, 2020, 11, 358.	1.0	0
57	Decisional Conflict after Deciding on Potential Participation in Early Phase Clinical Cancer Trials: Dependent on Global Health Status, Satisfaction with Communication, and Timing. Cancers, 2022, 14, 1500.	1.7	Ο